We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
DNA-methylation subgroups carry no prognostic significance in ATRT-SHH patients in clinical trial cohorts.
- Authors
Tran, Quynh T.; Upadhyaya, Santhosh A.; Billups, Catherine A.; Onar-Thomas, Arzu; Alom, Md. Zahangir; Carey, Steven S.; Robinson, Giles W.; Ellison, David W.; Gajjar, Amar; Orr, Brent A.
- Abstract
Consensus subgroup labels were reliably assigned to 41/43 cases, with 14 designated ATRT-SHH-1A, 11 ATRT-SHH-1B, and 16 ATRT-SHH-2 (Table S1). We also confirmed the previously observed difference in age at diagnosis with the ATRT-SHH-1B patients presenting at a median age of 3.5 years, compared to 1.1 years for both ATRT-SHH-1A and ATRT-SHH-2 ( I p i = 0.008).
- Subjects
METHYLGUANINE; CLINICAL trials; CENTRAL nervous system tumors
- Publication
Acta Neuropathologica, 2023, Vol 146, Issue 3, p543
- ISSN
0001-6322
- Publication type
Article
- DOI
10.1007/s00401-023-02614-9